Study of FT819 for B-cell autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 70 years old.
- You have a diagnosis of active lupus, vasculitis, myositis, or scleroderma that is moderate to severe.
- You have tried at least two treatments that did not work well enough.
- Your organs (heart, lungs, liver, kidneys) are working well enough to handle the treatment.
- You weigh at least 110 pounds (50 kilograms).
- You are not pregnant or nursing, and have no recent serious infections, cancer, or prior CAR T-cell therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new type of 'universal' CAR-T cell therapy (made from donor cells) combined with immune-suppressing drugs for people with severe autoimmune diseases that haven't responded to standard treatments. The goal is to see if this approach can control the immune system and reduce disease activity.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune rheumatic diseases like rheumatoid arthritis, lupus, or scleroderma that have not responded well to standard treatments. The therapy works by modifying your own immune cells to help control the disease.
Hear when a new Idiopathic Inflammatory Myositis (IIM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.